7.24
price up icon0.42%   0.03
after-market アフターアワーズ: 7.27 0.03 +0.41%
loading
前日終値:
$7.21
開ける:
$7.1
24時間の取引高:
2.15M
Relative Volume:
2.63
時価総額:
$498.18M
収益:
$46.02M
当期純損益:
$-70.80M
株価収益率:
-3.978
EPS:
-1.82
ネットキャッシュフロー:
$-1.61M
1週間 パフォーマンス:
+27.46%
1か月 パフォーマンス:
+9.04%
6か月 パフォーマンス:
-18.19%
1年 パフォーマンス:
-32.65%
1日の値動き範囲:
Value
$6.8625
$7.58
1週間の範囲:
Value
$5.57
$7.58
52週間の値動き範囲:
Value
$3.91
$13.98

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name
名前
Eyepoint Pharmaceuticals Inc
Name
セクター
Healthcare (1170)
Name
電話
617-926-5000
Name
住所
480 PLEASANT STREET, WATERTOWN, MA
Name
職員
144
Name
Twitter
@eyepointpharma
Name
次回の収益日
2025-03-05
Name
最新のSEC提出書
Name
EYPT's Discussions on Twitter

EYPT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
EYPT
Eyepoint Pharmaceuticals Inc
7.24 390.85M 46.02M -70.80M -1.61M -1.82
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-07 開始されました Citigroup Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-08-28 開始されました Jefferies Buy
2024-01-22 開始されました JP Morgan Overweight
2023-11-02 開始されました Mizuho Buy
2023-04-21 開始されました Robert W. Baird Outperform
2022-07-07 開始されました Chardan Capital Markets Buy
2021-03-01 開始されました Cowen Outperform
2021-01-28 開始されました Cantor Fitzgerald Overweight
2020-04-06 ダウングレード B. Riley FBR Buy → Neutral
2019-11-04 再開されました Laidlaw Buy
2019-09-12 開始されました Guggenheim Buy
すべてを表示

Eyepoint Pharmaceuticals Inc (EYPT) 最新ニュース

pulisher
May 30, 2025

EyePoint advances with Duravyu Phase III trial - Yahoo

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com

May 30, 2025
pulisher
May 30, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media

May 29, 2025
pulisher
May 29, 2025

Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga

May 29, 2025
pulisher
May 29, 2025

EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus

May 29, 2025
pulisher
May 28, 2025

EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times

May 28, 2025
pulisher
May 28, 2025

EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan

May 28, 2025
pulisher
May 27, 2025

EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada

May 27, 2025
pulisher
May 27, 2025

JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com

May 27, 2025
pulisher
May 27, 2025

Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus

May 27, 2025
pulisher
May 27, 2025

EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks

May 27, 2025
pulisher
May 27, 2025

EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq

May 27, 2025
pulisher
May 27, 2025

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times

May 27, 2025
pulisher
May 26, 2025

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail

May 26, 2025
pulisher
May 19, 2025

Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Insider Buying: Karen Zaderej Acquires Additional Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus

May 19, 2025
pulisher
May 16, 2025

EyePoint Pharmaceuticals (EYPT) Target Price Lowered by Mizuho Analyst | EYPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint (EYPT) Faces Price Target Reduction by Mizuho | EYPT St - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint price target lowered to $26 from $30 at Mizuho - TipRanks

May 16, 2025
pulisher
May 16, 2025

Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint (EYPT) Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

May 16, 2025
pulisher
May 16, 2025

EyePoint Awards Major Stock Options Package: 7 New Hires Receive 136,700 Shares at $5.72 - Stock Titan

May 16, 2025
pulisher
May 16, 2025

Mizuho cuts EyePoint Pharmaceuticals target to $26 By Investing.com - Investing.com India

May 16, 2025
pulisher
May 16, 2025

Mizuho cuts EyePoint Pharmaceuticals target to $26 - Investing.com

May 16, 2025
pulisher
May 15, 2025

Balyasny Asset Management L.P. Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat

May 15, 2025
pulisher
May 11, 2025

(EYPT) Technical Data - news.stocktradersdaily.com

May 11, 2025
pulisher
May 11, 2025

New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Yahoo Finance

May 11, 2025
pulisher
May 10, 2025

Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo

May 10, 2025
pulisher
May 10, 2025

Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN

May 10, 2025
pulisher
May 08, 2025

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 08, 2025
pulisher
May 08, 2025

EyePoint Pharmaceuticals (EYPT): Analyst Maintains Buy Rating, Lowers Price Target | EYPT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 08, 2025

EyePoint Pharma’s Promising Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals (EYPT) Reports Growth Amidst Trial Developments - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Transcript : EyePoint Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals Q1 2025 Earnings Preview - MSN

May 07, 2025
pulisher
May 07, 2025

Earnings call transcript: EyePoint Pharmaceuticals Q1 2025: Revenue Surges - Investing.com

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

EyePoint (EYPT) Sees Strong Q1 Revenue Growth and Advances in DURAVYU Trials | EYPT Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

EyePoint Pharmaceuticals Inc Surpasses Revenue Estimates with $24.5 Million in Q1 2025, EPS of ($0.65) Slightly Beats Expectations - GuruFocus

May 07, 2025

Eyepoint Pharmaceuticals Inc (EYPT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):